AKRX:NSD-Akorn, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 0.03

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

1.29M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-24 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

+2.25 (+9.10%)

USD9.19B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 32.94 11.89
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
PCRX Pacira BioSciences, Inc

+0.36 (+0.56%)

USD2.78B 22.85 62.06
CRON Cronos Group Inc

+0.68 (+9.26%)

USD2.61B 44.31 N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.23 (-1.92%)

USD1.92B 16.83 13.97
APHA Aphria Inc

+0.49 (+7.70%)

USD1.84B 57.50 454.68
ATNX Athenex, Inc

-0.11 (-0.79%)

USD1.31B N/A N/A
ENDP Endo International plc

+0.10 (+1.86%)

USD1.24B N/A 9.47
SUPN Supernus Pharmaceuticals, Inc

+0.53 (+2.56%)

USD1.09B 8.62 5.57

ETFs Containing AKRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -98.21% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.21% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -99.27% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.27% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -99.92% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.92% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -39.92% N/A N/A 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.92% N/A N/A 2% F
Risk Return Profile  
Volatility (Standard Deviation) 46.25% N/A N/A 25% F
Risk Adjusted Return -86.32% N/A N/A 5% F
Market Capitalization 0.01B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.20 N/A N/A N/A N/A
Price/Book Ratio 0.12 N/A N/A N/A N/A
Price / Cash Flow Ratio -0.32 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -231.80% N/A N/A N/A N/A
Return on Invested Capital -3.20% N/A N/A N/A N/A
Return on Assets -0.94% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.49 N/A N/A N/A N/A
Short Percent 10.29% N/A N/A N/A N/A
Beta 1.14 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.